Grown Rogue Reports First Quarter 2022 Results, aEBITDA of $1.0M
Grown Rogue International (CSE: GRIN, OTC: GRUSF) reported Q1 2022 revenue of $3.73M, up 255% from $1.05M in Q1 2021. Gross profit surged 310% to $2.03M, marking the ninth consecutive quarter of positive aEBITDA at $1.00M (26.9% margin). Strong growth was noted in Oregon (59% revenue rise) and Michigan (108% increase). The average selling price for indoor flower reached $1,062/pound. The company closed a private placement raising $1.30M. Grown Rogue is positioned as a leader in the Oregon flower market and anticipates further market share gains in 2022.
- Revenue increased by 255% to $3.73M.
- Gross profit rose 310% to $2.03M.
- aEBITDA increased to $1.00M, with a margin of 26.9%.
- Ninth consecutive quarter of positive aEBITDA.
- Closed a private placement raising $1.30M.
- Ranked as #1 indoor flower wholesaler in Oregon.
- Oregon revenue grew 59% and Michigan revenue increased by 108%.
- None.
-
Revenue of
compared to$3.73M in Q1 2021, an increase of$1.05M 255% -
Gross profit, before fair value adjustments, of
compared to$2.03M in Q1 2021, an increase of$0.50M 310% -
aEBITDA1 of
and aEBITDA1 margin of$1.00M 26.9% compared to aEBITDA1 of and aEBITDA1 margin of$0.05M 4.8% in Q1 2021 -
Segmented aEBITDA1 (excluding corporate costs) of
and segmented aEBITDA1 margin of$1.43M 38.3% -
Average selling price of indoor whole flower (excluding trim) of
per pound$1,062
First Quarter 2022 Financial Summary
- Ninth consecutive quarter of positive aEBITDA1, including pro-forma2 results
- Third consecutive quarter of positive operating cash flow, before changes in working capital
- Third consecutive quarter of positive net income
-
#1 indoor flower wholesaler in
Oregon , according to LeafLink’s MarketSpace data -
Named fastest growing brand in
Oregon during January, according to LeafLink; the third time in five months -
Net assets (excluding intangibles and goodwill) of
compared to$8.23M in net liabilities in Q1 2021$1.5M -
Closed a non-brokered private placement for gross proceeds of
which included an investment from$1.30M Bengal Capital , a venture capital firm with significant cannabis expertise, and the Company’s CEO -
Subsequent to quarter end,
Grown Rogue launched nitrogen sealed pre-rolls inMichigan
“Grown Rogue had a very strong quarter considering Q1 is typically the weakest quarter of our fiscal year”, said
Highlights by State
Oregon Operations
-
Revenue of
compared to$1.39M in Q1 2021, an increase of$0.87M 59% -
Gross profit, before fair value adjustments, of
compared to$0.70M in Q1 2021, an increase of$0.49M 41% -
Gross margin, before fair value adjustments, of
50.4% -
Segmented aEBITDA1 of
and aEBITDA1 margin of$0.41M 29.4% compared to segmented aEBITDA1 of and aEBITDA1 margin of$0.05M 4.8% in Q1 2021 -
Average selling price of indoor whole flower of
/pound$781 - Indoor production run rate expected to increase to 1,000 pounds in Q2 2022
-
#1 indoor flower wholesaler in
Oregon , according to LeafLink’s MarketSpace data -
Named fastest growing brand in
Oregon during January, according to LeafLink, and the third time in five months
Michigan Operations
-
Revenue of
compared to pro-forma2 revenue of$2.34M in Q1 2021, an increase of$1.13M 108% -
Gross margin, before fair value adjustments, of
57.0% -
Segmented aEBITDA1 of
and aEBITDA1 margin of$1.02M 43.5% compared to pro-forma2 segmented aEBITDA1 of and aEBITDA1 margin of$0.2M 18.8% -
Average selling price of indoor whole flower of
/pound$1,322 - Indoor production run rate expected to increase to 750 pounds/month in Q2 2022
-
Top 10 flower wholesaler in
Michigan , according to LeafLink’s MarketSpace data -
Subsequent to quarter end,
Grown Rogue launched nitrogen sealed pre-rolls
|
|
|
|
$ |
$ |
ASSETS |
|
|
Current assets |
||
Cash |
1,607,878 |
1,114,033 |
Accounts receivable |
1,029,971 |
739,248 |
Biological assets |
1,521,500 |
1,188,552 |
Inventory |
3,808,761 |
3,306,312 |
Prepaid expenses and other assets |
299,013 |
357,541 |
Total current assets |
8,267,123 |
6,705,686 |
Marketable securities |
426,823 |
610,092 |
Other investments and purchase deposits |
750,000 |
750,000 |
Property and equipment |
6,392,274 |
5,742,584 |
Intangible assets and goodwill |
399,338 |
399,338 |
TOTAL ASSETS |
16,235,558 |
14,207,700 |
LIABILITIES |
|
|
Current liabilities |
|
|
Accounts payable and accrued liabilities |
1,910,861 |
1,766,707 |
Current portion of lease liabilities |
1,117,642 |
624,935 |
Current portion of long-term debt |
1,192,916 |
843,900 |
Business acquisition consideration payable |
360,000 |
358,537 |
Interest payable |
15,000 |
13,750 |
Unearned revenue |
49,007 |
- |
Income tax |
269,133 |
254,631 |
Total current liabilities |
4,914,559 |
3,862,460 |
Accrued liabilities |
60,514 |
123,413 |
Lease liabilities |
1,589,584 |
1,735,503 |
Long-term debt |
1,046,259 |
1,365,761 |
TOTAL LIABILITIES |
7,610,916 |
7,087,137 |
EQUITY |
|
|
Share capital |
21,845,062 |
20,499,031 |
Shares issuable |
35,806 |
74,338 |
Contributed surplus |
6,462,732 |
6,407,935 |
Accumulated other comprehensive income (loss) |
(104,036) |
(90,378) |
Accumulated deficit |
(22,213,515) |
(21,804,349) |
Equity attributable to shareholders |
6,026,049 |
5,086,577 |
Non-controlling interest |
2,598,593 |
2,033,986 |
TOTAL EQUITY |
8,624,642 |
7,120,563 |
TOTAL LIABILITIES AND EQUITY |
16,235,558 |
14,207,700 |
|
Three months ended |
|
|
2022 |
2021 |
|
$ |
$ |
Revenue |
||
Product sales |
3,732,713 |
874,824 |
Service revenue |
- |
176,361 |
Total revenue |
3,732,713 |
1,051,185 |
Cost of goods sold |
||
Cost of finished cannabis inventory sold |
(1,699,026) |
(470,554) |
Cost of service revenues |
- |
(84,153) |
Gross profit, excluding fair value items |
2,033,687 |
496,478 |
Realized fair value amounts in inventory sold |
(1,010,478) |
(169,328) |
Unrealized fair value gain (loss) on growth of biological assets |
1,289,514 |
(186,806) |
Gross profit |
2,312,723 |
140,344 |
Expenses |
||
Accretion expense |
151,687 |
248,357 |
Amortization of intangible assets |
- |
4,997 |
Amortization of property & equipment |
52,010 |
38,155 |
General and administrative |
1,603,926 |
666,739 |
Share-based compensation |
18,487 |
88,438 |
Total expenses |
1,826,110 |
1,046,686 |
Gain (loss) from operations |
482,593 |
(906,342) |
Other income and (expense) |
||
Interest expense |
(114,660) |
(8,527) |
Other income |
(5,440) |
- |
Gain on debt settlement |
- |
16,623 |
Unrealized gain (loss) on marketable securities |
(167,804) |
302,808 |
Unrealized loss on derivative liability |
- |
(319,627) |
Gain (loss) on disposal of property and equipment |
(6,250) |
- |
Gain from operations before taxes |
192,459 |
(915,065) |
Income tax |
(37,018) |
- |
Net income (loss) |
155,441 |
(915,065) |
Other comprehensive income (items that may be subsequently reclassified to profit & loss) |
||
Currency translation |
(13,658) |
(75,934) |
Total comprehensive income (loss) |
141,783 |
(990,999) |
Gain (loss) per share attributable to owners of the parent – basic & diluted |
- |
(0.01) |
Weighted average shares outstanding – basic & diluted |
164,976,815 |
108,038,431 |
Net income (loss) for the period attributable to: |
||
Non-controlling interest |
564,607 |
4,896 |
Shareholders |
(409,166) |
(919,961) |
Net income (loss) |
155,441 |
(915,065) |
Comprehensive loss for the period attributable to: |
||
Non-controlling interest |
564,607 |
4,896 |
Shareholders |
(422,824) |
(995,895) |
Total comprehensive income (loss) |
141,783 |
(990,999) |
Quarter ended |
|
|
Corporate |
Consolidated |
Sales revenues |
1,388,945 |
2,343,768 |
- |
3,732,713 |
Costs of goods sold, excluding fair value adjustments |
(691,311) |
(1,007,715) |
- |
(1,699,026) |
Gross profit (loss) before fair value adjustments |
697,634 |
1,336,053 |
- |
2,033,687 |
Net fair value adjustments |
474,511 |
(195,475) |
- |
279,036 |
Gross profit |
1,172,145 |
1,140,578 |
- |
2,312,723 |
Operating expenses: |
- |
|||
General and administration |
341,037 |
739,196 |
523,693 |
1,603,926 |
Depreciation and amortization |
7,041 |
19,166 |
25,803 |
52,010 |
Share based compensation |
- |
- |
18,487 |
18,487 |
Other income and expense: |
- |
- |
- |
|
Gain on sale of assets |
6,250 |
- |
- |
6,250 |
Interest and accretion |
77,387 |
74,494 |
114,466 |
266,347 |
Unrealized loss (gain) on
|
- |
- |
167,804 |
167,804 |
Other income and expense |
- |
- |
5,440 |
5,440 |
Net income (loss) before tax |
740,430 |
307,722 |
(855,693) |
192,459 |
Tax |
2,951 |
34,067 |
- |
37,018 |
Net income after tax |
737,479 |
273,655 |
(855,693) |
155,441 |
|
Three months ended |
|
|
|
|
Adjusted EBITDA Reconciliation |
2022 ($) |
2021 ($) |
Net income (loss), as reported |
155,441 |
(915,065) |
Add back realized fair value amounts included in inventory sold |
1,010,478 |
169,328 |
Add back (deduct) unrealized fair value gain (loss) on
|
(1,289,514) |
186,806 |
Add back amortization of property & equipment included in cost of sales |
147,463 |
159,545 |
|
23,868 |
(399,386) |
Add back interest and interest accretion expense, as reported |
266,347 |
256,884 |
Add back amortization of intangible assets, as reported |
- |
4,997 |
Add back amortization of property and equipment, as reported |
52,010 |
38,155 |
Add back share-based compensation |
62,296 |
132,448 |
Add back (deduct) unrealized loss (gain) on marketable
|
167,804 |
(302,808) |
Add back (deduct) unrealized loss (gain) on derivative liability |
319,627 |
|
Add back income tax expense |
37,018 |
- |
EBITDA before other adjustments |
609,343 |
49,917 |
Performance incentive bonus payment |
179,685 |
- |
Severance and inactive employee compensation |
61,077 |
- |
Business development incentive bonus |
153,825 |
- |
Adjusted EBITDA |
1,003,930 |
49,917 |
About
NOTES:
1.
The Company’s “aEBITDA” is a non-IFRS measure used by management that does not have any prescribed meaning by IFRS and that may not be comparable to similar measures presented by other companies. The Company defines aEBITDA as the Company’s net income (loss) for a period, as reported, before interest, taxes, depreciation and amortization, and is further adjusted to remove transaction costs, stock-based compensation expense, accretion expense, gain (loss) on derecognition of derivative liabilities and the effects of fair-value accounting for biological assets and inventory, as well as the impacts of unusual or non-recurring items. The Company believes that this is a useful metric to evaluate its operating performance.
2.
The Company has provided unaudited pro-forma revenue information, which assumes that closed and pending mergers and acquisitions in 2021 are included in the Company’s financial results as of the beginning of the quarterly and annual periods in 2021 for the Company and target companies.
NON-IFRS FINANCIAL MEASURES
Cash production costs of
About
FORWARD-LOOKING STATEMENTS
This press release contains statements which constitute “forward‐looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities. Forward‐ looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions and include information regarding: (i) statements regarding the future direction of the Company (ii) the ability of the Company to successfully achieve its business and financial objectives, (iii) plans for expansion of the Company into
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law.
SAFE HARBOR STATEMENT
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, its directors or its officers with respect to, among other things: (i) the Company’s financing plans; (ii) trends affecting the Company’s financial condition or results of operations; (iii) the Company’s growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors including the risk disclosed in the Company’s Form 20-F and 6-K filings with the
The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational cannabis marketplace in
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
For further information on
View source version on businesswire.com: https://www.businesswire.com/news/home/20220404005271/en/
Chief Executive Officer
obie@grownrogue.com
Investor Relations Desk Inquiries
invest@grownrogue.com
(458) 226-2100
Source:
FAQ
What were Grown Rogue International's Q1 2022 revenue figures?
How did Grown Rogue's gross profit perform in Q1 2022?
What is the aEBITDA for Grown Rogue in Q1 2022?
What is Grown Rogue's market position in Oregon?